A detailed history of Tower Research Capital LLC (Trc) transactions in Kronos Bio, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 4,123 shares of KRON stock, worth $3,916. This represents 0.0% of its overall portfolio holdings.

Number of Shares
4,123
Previous 5,540 25.58%
Holding current value
$3,916
Previous $6,000 33.33%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$0.92 - $1.5 $1,303 - $2,125
-1,417 Reduced 25.58%
4,123 $4,000
Q2 2024

Aug 13, 2024

SELL
$0.73 - $1.38 $7,043 - $13,315
-9,649 Reduced 63.53%
5,540 $6,000
Q1 2024

May 15, 2024

BUY
$1.02 - $1.3 $15,419 - $19,652
15,117 Added 20995.83%
15,189 $19,000
Q4 2023

Feb 13, 2024

BUY
$0.75 - $1.49 $54 - $107
72 New
72 $0
Q1 2023

May 09, 2023

SELL
$1.34 - $2.62 $17,261 - $33,750
-12,882 Reduced 64.59%
7,062 $10,000
Q4 2022

Feb 10, 2023

BUY
$1.44 - $3.44 $4,291 - $10,251
2,980 Added 17.57%
19,944 $32,000
Q3 2022

Nov 10, 2022

BUY
$3.35 - $5.55 $45,747 - $75,790
13,656 Added 412.82%
16,964 $57,000
Q2 2022

Aug 15, 2022

BUY
$3.12 - $7.52 $2,243 - $5,406
719 Added 27.77%
3,308 $12,000
Q1 2022

May 12, 2022

SELL
$6.26 - $14.42 $8,738 - $20,130
-1,396 Reduced 35.03%
2,589 $19,000
Q4 2021

Feb 14, 2022

BUY
$11.35 - $21.18 $34,242 - $63,900
3,017 Added 311.67%
3,985 $54,000
Q3 2021

Nov 15, 2021

SELL
$18.17 - $24.7 $9,157 - $12,448
-504 Reduced 34.24%
968 $21,000
Q2 2021

Aug 16, 2021

BUY
$20.08 - $29.02 $13,774 - $19,907
686 Added 87.28%
1,472 $35,000
Q1 2021

May 17, 2021

SELL
$27.0 - $32.48 $513 - $617
-19 Reduced 2.36%
786 $23,000
Q4 2020

Feb 16, 2021

BUY
$26.68 - $38.23 $21,477 - $30,775
805 New
805 $24,000

Others Institutions Holding KRON

About Kronos Bio, Inc.


  • Ticker KRON
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,769,100
  • Market Cap $53.9M
  • Description
  • Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally...
More about KRON
Track This Portfolio

Track Tower Research Capital LLC (Trc) Portfolio

Follow Tower Research Capital LLC (Trc) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

News

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.